Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc.

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: 1h ago

0mins

RARE+3.83%

Should l Buy RARE?

Source: Globenewswire

Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and certain officers, seeking damages for investors who acquired Ultragenyx securities between August 3, 2023, and December 26, 2025.
False Statements Allegation: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study for Osteogenesis Imperfecta (OI), leading investors to have an unwarranted optimistic view of the study's results.
Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery, with the assurance that participation does not require serving as lead plaintiff.
Law Firm's Reputation: Bronstein, Gewirtz & Grossman, LLC is well-regarded in securities fraud class actions, having recovered hundreds of millions for investors nationwide, emphasizing its commitment to restoring investor capital and ensuring corporate accountability.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.

RARE

$24.7+Infinity%1D

Analyst Views on RARE

Wall Street analysts forecast RARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RARE is 61.65 USD with a low forecast of 35.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

18 Analyst Rating

17 Buy

1 Hold

0 Sell

Strong Buy

Current: 23.790

Low

35.00

Averages

61.65

High

120.00

Current: 23.790

Low

35.00

Averages

61.65

High

120.00

Barclays

Eliana Merle

Overweight

initiated

$44

2026-01-27

Reason

Barclays

Eliana Merle

Price Target

$44

AI Analysis

2026-01-27

initiated

Overweight

Reason

Barclays analyst Eliana Merle assumed coverage of Ultragenyx with an Overweight rating and $44 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."

Morgan Stanley

Maxwell Skor

Overweight

downgrade

$55 -> $50

2026-01-08

Reason

Morgan Stanley

Maxwell Skor

Price Target

$55 -> $50

2026-01-08

downgrade

Overweight

Reason

Morgan Stanley analyst Maxwell Skor lowered the firm's price target on Ultragenyx to $50 from $55 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RARE

Unlock Now

About RARE

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Ultragenyx Resubmits BLA for Accelerated Approval of UX111 Gene Therapy

1 day agoYahoo Finance

Application Progress: On January 30, Ultragenyx Pharmaceutical resubmitted its Biologics License Application (BLA) to the FDA for accelerated approval of UX111 AAV9 gene therapy for Sanfilippo syndrome type A, with a review expected in Q3; if approved, it will be the first therapy for this condition.
Market Analyst Support: Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ultragenyx with a price target of $50, reflecting confidence in the company's growth potential, while Leerink Partners also issued a Buy rating, indicating positive investor sentiment.
Diverse Product Line: Ultragenyx focuses on therapies for rare and ultra-rare genetic diseases, with products like Crysvita, Mepsevii, Dojolvi, and Evkeeza, showcasing its broad market presence and potential in the biopharmaceutical sector.
Investment Outlook Assessment: While RARE is viewed as a promising investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, urging investors to carefully evaluate market dynamics to optimize their portfolios.